WO2007008514A3 - Inhibitors of glycogen synthase kinase 3 - Google Patents
Inhibitors of glycogen synthase kinase 3 Download PDFInfo
- Publication number
- WO2007008514A3 WO2007008514A3 PCT/US2006/026137 US2006026137W WO2007008514A3 WO 2007008514 A3 WO2007008514 A3 WO 2007008514A3 US 2006026137 W US2006026137 W US 2006026137W WO 2007008514 A3 WO2007008514 A3 WO 2007008514A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- glycogen synthase
- synthase kinase
- relates
- disease
- present
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
One aspect of the present invention relates to heterocyclic compounds that inhibit mammalian or human glycogen synthase kinase 3. Another aspect of the invention relates to pharmaceutical compositions comprising such a heterocyclic compound. The present invention also relates to methods of treating a mammal or human suffering from a malady that is based at least in part on abnormal activity of glycogen synthase kinase 3. The present invention also relates to methods of treating a mammal or human suffering from diabetes, Alzheimer's disease, Huntington's disease, Parkinson's disease, AIDS-associated dementia, ALS, MS, or schizophrenia.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US69708405P | 2005-07-07 | 2005-07-07 | |
US60/697,084 | 2005-07-07 | ||
US71727705P | 2005-09-15 | 2005-09-15 | |
US60/717,277 | 2005-09-15 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2007008514A2 WO2007008514A2 (en) | 2007-01-18 |
WO2007008514A3 true WO2007008514A3 (en) | 2007-10-04 |
Family
ID=37637714
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2006/026137 WO2007008514A2 (en) | 2005-07-07 | 2006-07-06 | Inhibitors of glycogen synthase kinase 3 |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2007008514A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9486441B2 (en) | 2008-04-21 | 2016-11-08 | Signum Biosciences, Inc. | Compounds, compositions and methods for making the same |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008077138A1 (en) | 2006-12-19 | 2008-06-26 | The Board Of Trustees Of The University Of Illinois | 3-benzofuranyl-4-indolyl maleimides as potent gsk3 inhibitors for neurogenerative disorders |
UY34072A (en) | 2011-05-17 | 2013-01-03 | Novartis Ag | INDOL SUBSTITUTED DERIVATIVES |
JP2016508962A (en) * | 2012-12-10 | 2016-03-24 | セントジーン アーゲー | Use of maleimide derivatives to prevent and treat cancer |
JP2016504299A (en) * | 2012-12-10 | 2016-02-12 | セントジーン アーゲー | Use of maleimide derivatives to prevent and treat leukemia |
KR102662172B1 (en) | 2015-04-24 | 2024-04-29 | 루브리졸 어드밴스드 머티어리얼스, 인코포레이티드 | Surface modified polymer composition |
CN106699739B (en) * | 2016-12-16 | 2019-03-12 | 浙江工业大学上虞研究院有限公司 | 3- indoles -4- indazole maleimide compound and its preparation method and application |
AU2020218366A1 (en) | 2019-02-08 | 2021-09-16 | Frequency Therapeutics, Inc. | Valproic acid compounds and Wnt agonists for treating ear disorders |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6849643B2 (en) * | 2000-12-08 | 2005-02-01 | Ortho-Mcneil Pharmaceutical, Inc. | Indazolyl-substituted pyrroline compounds as kinase inhibitors |
-
2006
- 2006-07-06 WO PCT/US2006/026137 patent/WO2007008514A2/en active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6849643B2 (en) * | 2000-12-08 | 2005-02-01 | Ortho-Mcneil Pharmaceutical, Inc. | Indazolyl-substituted pyrroline compounds as kinase inhibitors |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9486441B2 (en) | 2008-04-21 | 2016-11-08 | Signum Biosciences, Inc. | Compounds, compositions and methods for making the same |
Also Published As
Publication number | Publication date |
---|---|
WO2007008514A2 (en) | 2007-01-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2007008514A3 (en) | Inhibitors of glycogen synthase kinase 3 | |
WO2007120980A3 (en) | 2,4-pyrimidinediamine compounds for treating or preventing autoimmune diseases | |
WO2007070434A3 (en) | Fused aminopiperidines as dipeptidyl peptidase-4 inhibitors for the treatment or prevention of diabetes | |
WO2007079199A3 (en) | Substituted bis-amide metalloprotease inhibitors | |
WO2008005956A3 (en) | Pyrrolotriazine kinase inhibitors | |
WO2010048149A3 (en) | Heterocyclic modulators of gpr119 for treatment of disease | |
WO2007059230A3 (en) | Substituted 1h-benzimidazole-4-carboxamides are potent parp inhibitors | |
WO2007070359A3 (en) | Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions, and uses thereof | |
WO2009117421A3 (en) | Heterocyclic modulators of gpr119 for treatment of disease | |
WO2007079214A3 (en) | Prokineticin 2 receptor antagonists | |
TW200716163A (en) | A therapeutic agent for aβ related disorders | |
WO2006107859A3 (en) | Dihydropyridine compounds for neurodegenerative diseases and dementia | |
WO2006110816A3 (en) | 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors | |
WO2007087231A3 (en) | Aminocyclohexanes as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes | |
WO2007126745A3 (en) | Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes | |
NZ595571A (en) | Pyrazole compounds and uses thereof | |
WO2007127505A3 (en) | Use of sulfonamide derivatives in the treatment of disorders of the metabolism and the nervous system | |
WO2009127642A3 (en) | Use of lrrk2 inhibitors for neurodegenerative diseases | |
WO2006099379A3 (en) | Benzazole derivatives, compositions, and methods of use as b-secretase inhibitors | |
TW200630356A (en) | Polymorphic forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridin-2-yl)ethenyl]indazole | |
EP1740559A4 (en) | 1,3,5-substituted phenyl derivative compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease | |
WO2005086656A3 (en) | Heteroarylaminopyrazole derivatives useful for the treatment of diabetes | |
WO2005115145A3 (en) | Quinone substituted quinazoline and quinoline kinase inhibitors | |
WO2006057945A3 (en) | 2,3,4,6-substituted pyridyl derivative compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease | |
IL186777A0 (en) | (3,4-dihydro-quinazolin-2-yl) - (2-aryloxy-ethyl) - amines having an activity on the 5 - ht receptor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 06786326 Country of ref document: EP Kind code of ref document: A2 |